From OpenWetWare
Jump to navigationJump to search

iGEM 2008

Home        People        Project        Protocols        Notes        Ideas        Changes       

We aim to engineer a probiotic bacterium to improve its medical applications. Our work focuses on four main areas: (1) pathogen defense, either by expression of pathogen-specific bacteriophage or by targeted bursts of reactive oxygen species; (2) vitamin over-expression and delivery; (3) treatment of lactose intolerance, by preferentially metabolizing lactose and funneling it to vitamin production; and (4) regulation of these three treatment functions to produce subpopulations specialized for each function.

Vitamin Production

Tasty foods containing folate

Folate is the generic term for the various forms of Vitamin B9, which include dihydrofolate (DHF), tetrahydrofolate (THF), and folic acid. An essential vitamin for cell survival, folate is involved in amino synthesis (and thus DNA synthesis) as well as single-carbon-transfer reactions. Though humans don't produce folate, folate deficiency can cause serious birth defects and anemia. As a result, most cereals and breads are supplemented with folate. Folate has also been shown to have good bioavailability in the large intestine, and so is more easily absorbed by the host than other vitamins.

Our aim is to engineer a strain of E. coli that will overexpress folate such that a person without access to green, leafy vegetables or folate-supplemented foods can still obtain the necessary daily amount by having this strain residing in their gut.

Lactose intolerance

Lactose intolerance is the inability to metabolize lactose in the small intestine. For a non lactose intolerant person, he or she is able to express β-galactosidase in the small intestine which cleaves lactose into glucose and galactose. Glucose and galactose are then taken up by the host. For a lactose intolerant person, lactose travels passed the small intestine into the large intestine where it is metabolized by the gut flora. The osmolarity changes in the large intestine due to the large amounts of sugar, pulling more water into the large intestine. Due to this rush of water, lactose intolerant persons may experience diarrhea. Lactose is metabolized in this order: Lactose --> glucose + galactose --> lactic acid + acetic acid --> H2 --> methane. A different bacteria is involved in each step, so we can't engineer our strain to metabolize lactose, because it will eventually get metabolized into methane, which is the cause of abdominal pain and unwanted gas.

Instead, we will engineer a strain of E. coli that will express the β-Gal gene in the large intestine to quickly cleave lactose. The host will then be able to reabsorb the glucose and galactose from the large intestine.

Oxidative Burst

A neutrophil trapping Shigella

Several types of bacteria can cause illness in humans by infecting the gut. Salmonella and E. coli are probably the two people most frequently associate with food poisoning. There are other pathogenic bacteria that can infect our gut as well. Shigella and Campylobacter can cause cramping, diarrhea and dysentery. Vibrio cholerae, which also infects the gut, is the cause of cholera. The body normally relies on white blood cells (neutrophils) to clear bacteria from the body. Once a bacterium is engulfed, the neutrophil releases a sudden and toxic amount of reactive oxygen species, comprised of a mixture of superoxide, hydrogen peroxide, and hypochlorous acid. This is event is termed the oxidative burst. However, white blood cells do not patrol the gut lumen and so there is no active clearance of pathogens. The goal of this project is to engineer a beneficial gut microbe capable of detecting a harmful bacterium and, in turn, generate an oxidative burst sufficient to kill the pathogen.

Phage Pathogen Defense

Phage attached to bacteria, electron micrograph

Another aspect of bacterial pathogen defense for our probiotic is to produce bacteriophages, which would rapidly infect and wipe out all of the pathogens. There are basically methods to approach phage production, differentiated by the type of phage used. The first uses the bacteriophage λ, which targets E. Coli. The other is exploring the use of a temperate bacteriophage from B. Subtilis, however this method, if successful, can be adapted to temperate bacteriophages of any bacterial strain.

Bacteriophage λ is a temperate phage with an E. Coli. host, λ infects E. Coli through the lamB receptor, and absence of this receptor prevents λ infection. We will takes advantage of this aspect of bacteriophage λ to create E. Coli which are resistant to the phage, but release the phage to destroy susceptible pathogenic E. Coli.

The second approach is more versatile, and can target more strains of pathogenic bacteria. The goal is to create a phasmid out of the genome of a temperate bacteriophage. A phasmid combines a E. Coli plasmid Origin of Replication with a linear phage genome, circularizing it. This allows the phasmid to pass on as a plasmid within E. Coli, however when transferred to its native host, the phage phage is induced.

Asynchronous Random State Generator

Given that we have created four different states for a cell to be in, we need to in some manner combine them into one system. However, we need to ensure that any particular cell is in only one of these states, and not more than one, or else the load on the cell may be too big. In other words, we want to make these states mutually exclusive.

To do so, two new devices have been created: a randomly activated off-to-on switch and a population variation generator. Initially, a cell is in a default state (S0), the switch is off, and the fate of the cell is undetermined. However, each time a cell replicates the plasmid that contains the switch, there is a chance that the switch turns on. Once the switch is on, it activates the population variation generator, which in turn determines the fate of the cell by setting it to one of three states - S1, S2, or S0 (the original default). That cell and all of its descents then stay in the determined state.

  1. Hooper LV, Midtvedt T, and Gordon JI. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr. 2002;22:283-307. DOI:10.1146/annurev.nutr.22.011602.092259 | PubMed ID:12055347 | HubMed [hooper]
  2. Mazmanian SK, Liu CH, Tzianabos AO, and Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005 Jul 15;122(1):107-18. DOI:10.1016/j.cell.2005.05.007 | PubMed ID:16009137 | HubMed [mazmanian]
  3. Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis. 2004 Jul 15;39(2):219-26. DOI:10.1086/422002 | PubMed ID:15307031 | HubMed [donskey]
  4. Krammer HJ, Kämper H, von Bünau R, Zieseniss E, Stange C, Schlieger F, Clever I, and Schulze J. [Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3,807 patients]. Z Gastroenterol. 2006 Aug;44(8):651-6. DOI:10.1055/s-2006-926909 | PubMed ID:16902895 | HubMed [krammer]
  5. Westendorf AM, Gunzer F, Deppenmeier S, Tapadar D, Hunger JK, Schmidt MA, Buer J, and Bruder D. Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules. FEMS Immunol Med Microbiol. 2005 Mar 1;43(3):373-84. DOI:10.1016/j.femsim.2004.10.023 | PubMed ID:15708311 | HubMed [westendorf]
  6. Rao S, Hu S, McHugh L, Lueders K, Henry K, Zhao Q, Fekete RA, Kar S, Adhya S, and Hamer DH. Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):11993-8. DOI:10.1073/pnas.0504881102 | PubMed ID:16040799 | HubMed [rao]
  7. Duan F and March JC. Interrupting Vibrio cholerae infection of human epithelial cells with engineered commensal bacterial signaling. Biotechnol Bioeng. 2008 Sep 1;101(1):128-34. DOI:10.1002/bit.21897 | PubMed ID:18433007 | HubMed [duan]
  8. Suttie JW. The importance of menaquinones in human nutrition. Annu Rev Nutr. 1995;15:399-417. DOI:10.1146/annurev.nu.15.070195.002151 | PubMed ID:8527227 | HubMed [suttie]
All Medline abstracts: PubMed | HubMed